WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Insulin degludec

Governed registry record

2 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Approved source records

  1. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.

    DOI: 10.1016/s2213-8587(22)00070-5

    Source identity and connection checked by Codex (AI).

  2. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

    DOI: 10.1016/s0140-6736(21)01443-4

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Gastaldelli A
  • Cusi K
  • Fernández Landó L
  • Bray R
  • Brouwers B
  • Rodríguez Á
  • Lingvay I
  • Asong M
  • Desouza C
  • Gourdy P
  • Kar S
  • Vianna A
  • Vilsbøll T
  • Vinther S
  • Mu Y
  • Ludvik B
  • Giorgino F
  • Jódar E
  • Frias JP
  • Brown K
  • Baker DE